(5S)-3-benzyl-5-ethyl-5-phenylimidazolidine-2,4-dione

• ChemBase编号: 154018
• 分子式: C18H18N2O2
• 平均质量: 294.34772
• 单一同位素质量: 294.13682783
• SMILES: CC[C@@]1(C(=O)N(C(=O)N1)Cc1ccccc1)c1ccccc1
• Canonical SMILES: CC[C@]1(NC(=O)N(C1=O)Cc1ccccc1)c1ccccc1
• InChI: InChI=1S/C18H18N2O2/c1-2-18(15-11-7-4-8-12-15)16(21)20(17(22)19-18)13-14-9-5-3-6-10-14/h3-12H,2,13H2,1H3,(H,19,22)/t18-/m0/s1
• InChIKey: ZMZDHUHMXXALFX-SFHVURJKSA-N

名称和登记号

名称

• IUPAC标准名: (5S)-3-benzyl-5-ethyl-5-phenylimidazolidine-2,4-dione
• IUPAC传统名: (5S)-3-benzyl-5-ethyl-5-phenylimidazolidine-2,4-dione
• 别名: (+)-N-3-Benzyl Nirvanol; (5S)-5-Ethyl-5-phenyl-3-(phenylmethyl)-2,4-imidazolidinedione; 5-ethyl-5-phenyl-3-(phenylmethyl)-2,4-imidazolidinedione; 5-ethyl-5-phenyl-3-(phenylmethyl)-hydantoin; 5-Ethyl-5-phenyl-3-(phenylmethyl)hydantoin; (+)-N-3-Benzylnirvanol; (S)-(+)-N-3-Benzylnirvanol

登记号

• CAS号: 790676-40-3
• MDL号: MFCD09840024
• PubChem SID: 162248157
• PubChem CID: 40633600

理论计算性质

• Acid pKa: 11.207963
• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): 3.3896456
• LogD (pH = 7.4): 3.3895795
• Log P: 3.3896463
• 摩尔折射率: 84.1506 cm^3
• 极化性: 32.652225 Å^3
• 极化表面积: 49.41 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO; DMSO: >20 mg/mL; H2O: insoluble; Methanol
• 外观: Off-White Solid; powder
• 熔点: 147-150°C

安全信息

• 保存条件: -20°C Freezer
• 欧盟危险性物质标志: 环境危害性(Nature polluting) (N); 有害性(Harmful) (Xn)
• 联合国危险货物编号: 3077
• 德国WGK号: 3
• 联合国危险货物等级: 9
• 联合国危险货物包装类别(PG): 3
• 危险公开号: 22-36-50
• 安全公开号: 26-61
• GHS危险品标识: GHS07; GHS09
• GHS警示词: Warning
• GHS危险声明: H302-H319-H400
• GHS警示性声明: P273-P305 + P351 + P338
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• RID/ADR: UN 3077 9/PG 3
• 保存温度: 2-8°C

产品相关信息

• 纯度: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C18H18N2O2

详细说明

Sigma Aldrich - B8686

Biochem/physiol Actions
(+)-N-3-Benzyl-nirvanol is a potent selective CYP2C19 inhibitor. CYP2C19 has a high frequency of drug resistance; highly polymorphic.

Toronto Research Chemicals - B285775

It is a potent and selective human CYP2C19 inhibitor.

参考文献

• Suzuki, H., et al.: Drug Metab. Dispos., 30, 235 (2002)
• Robert, L., et al.: Drug Metab. Dispos., 31, 343 (2002)